The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold
andsoitis
60 points
6 comments
July 17, 2026
Related Discussions
Found 5 related stories in 149.0ms across 5,346 title embeddings via pgvector HNSW
- AI in drug discovery – what it is, where we stand and the path forward AnodicElegy · 123 pts · August 15, 2026 · 55% similar
- Why haven't organoids solved all of drug discovery? crescit_eundo · 18 pts · July 28, 2026 · 55% similar
- Our Approach to Bioresilience: Isomorphic Labs and Google DeepMind bookofjoe · 76 pts · July 18, 2026 · 52% similar
- Ox Alpha – A mysterious new AI model vismit2000 · 11 pts · August 25, 2026 · 51% similar
- First human trials of designer protein therapies stun US neuroscientists gradus_ad · 27 pts · August 15, 2026 · 49% similar
Discussion Highlights (5 comments)
ashwon13
Would like more details technically on their approach. Is it a neuro-symbolic approach, do they do something beyond just scaling, or some other architecture breakthrough, but alas drug discovery must remain proprietary. Thank gods for capitalism!
bonsai_spool
This is from February 2026 and notably there’s no way for the public to try out the model, nor is it published in a peer-reviewed journal
tusimi
"In November 2024, preliminary results of CASP16 showed AlphaFold 3-based models did not significantly outperform older methods for predicting protein-ligand interactions. The top performing models in the CASP16 Pose Prediction for Pharma Targets section were ClusPro[13] and CoDock[14] utilizing AlphaFold 2 based predictions, human visual inspection, and manual adjustments.[15] In April 2025 Isomorphic Labs raised $600 Million in its first ever external funding round, led by Thrive Capital.[16][17]" https://en.wikipedia.org/wiki/Isomorphic_Labs
navvyeanand
This is old news.
puttycat
What technical advancement made this possible? The text is vague about this.